Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Ravulizumab for Thrombotic Microangiopathy
Recruiting1 awardPhase 3
Kansas City, Kansas
This trial will study whether a new drug, ravulizumab, is effective and safe for treating a condition called HSCT-TMA. The trial will have two stages: in the first stage, participants will receive the drug to see what dose works best; in the second stage, participants will be randomly assigned to receive either the drug or a placebo, and the effects of the drug will be compared to the placebo. The trial will last for 52 weeks total, with 26 weeks of treatment and 26 weeks of follow-up.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.